Companies 0 See All

Hedge Funds 0 See All

Insiders 0 See All

Institutional Investors 0 See All

Click here to see all results for

Home > Insider Trading > Filing (0001235802-23-000110)

Filing Details

Accession Number:: 0001235802-23-000110
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-11-08 16:16:25
Reporting Period:: 2023-08-04

Accepted Time:: 2023-11-08 16:16:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1427570	Reshape Lifesciences Inc.	RSLS	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1181166	Thomas Stankovich	1001 Calle Amanecer San Clemente CA 92673	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, $0.001 Par Value Per Share	Disposition	2023-08-04	108	$1.43	23,276	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-08-24	39	$1.42	23,237	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-09-01	118	$0.89	23,119	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-10-11	39	$0.93	23,080	No	4	S	Direct
Common Stock, $0.001 Par Value Per Share	Disposition	2023-10-25	131	$0.27	22,949	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.